Telix Pharmaceuticals (TLPPF) Notes Payables (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Notes Payables for 4 consecutive years, with $11.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Notes Payables changed N/A year-over-year to $11.5 million in Q2 2026; TTM through Jun 2026 was $11.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $13.1 million, up 11.45% from the prior year.
• Notes Payables was $11.5 million for Q2 2026 at Telix Pharmaceuticals, down from $13.1 million in the prior quarter.
• Over five years, Notes Payables peaked at $13.1 million in Q4 2025 and troughed at $627554.8 in Q4 2023.
• A 4-year average of $9.4 million and a median of $12.0 million in 2024 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables soared 1878.89% in 2024 and gained 5.57% in 2025, its largest moves.
• Over 4 years, Notes Payables stood at $627554.8 in 2023, then soared by 1878.89% to $12.4 million in 2024, then advanced by 5.57% to $13.1 million in 2025, then retreated by 12.22% to $11.5 million in 2026.
• The last three Notes Payables figures came in at $11.5 million (Q2 2026), $13.1 million (Q4 2025), and $12.4 million (Q4 2024), per Business Quant data.